Carcinoid tumour is the most obvious and straightforward example of neuroendocrine cell neoplasia, but occasionally the distinction between hyperplasia and neoplasia becomes blurred and it is possible to demonstrate proliferation of neuroendocrine cells adjacent to the tumour and elsewhere in the lung. 24 At the ultrastructural level endocrine function is associated with the presence of dense core secretory granules, and the discovery of identical granules in small cell lung carcinoma, typically in very small numbers and confined to cell processes, was initially interpreted as evidence that this tumour also arose from neuroendocrine cells. 14 18 19 Such differences are difficult to explain.
The presence of raised serum levels of chromogranin in patients with small cell lung carcinoma indicates that it may not always be confined to granules, but there is no evidence that free immunoreactive chromogranin is present in tumour cells. 20 Most commercial antibodies to synaptophysin are derived from the SY38 clone and give inconsistent results in formalin fixed, paraffin embedded tissue. The use of fresh tissue or alternative fixatives has been recommended, but new antigen retrieval techniques should make this unnecessary.21 22 In the series reported by Gosney et al, in which routinely fixed and processed tissue was used without antigen retrieval, most small cell tumours and a small number of non-small cell tumours were positive. Similar results have been reported previously and synatophysin is emerging as one of the most useful markers.23
Normal and neoplastic lung cells synthesise several hormonally active peptides including gastrin releasing peptide (GRP), ACTH, and the pro-opiomelanocortin-related peptides, arginine vasopressin, calcitonin and calcitonin gene related peptide, ACTH, Leu-encephalin, and substance P. At first sight it would seem attractive to use antibodies to these peptides to determine neuroendocrine differentiation in carcinomas. However, detection depends on a sufficient amount ofthe normal peptide being stored in the cell. In well differentiated endocrine tumours (carcinoid tumours) peptides are usually easily identifiable, but where neurosecretory granules are sparse, staining, if detectable at all, is focal and variable in intensity; none was identified by Gosney et al. Another possible reason for this is that most peptides are produced as larger precursor molecules and cleavage is required before the active peptide is available for storage or release. For example, GRP -which acts as an autocrine growth factor for small cell lung carcinoma -is produced as prepro-GRP. 24 25 There is some evidence that part of this larger molecule, more specifically the Nterminal fragment, could be a more consistent marker of malignant neuroendocrine tumours than GRP itself. 25 If cell constituents and peptides are unreliable markers, a logical step is to identify the genetic material coding for the markers of neuroendocrine differentiation. Small cell lung carcinoma cells, which contain very little stored chromogranin, contain cytoplasmic chromogranin mRNAs that are readily detectable by in situ hybridisation.'8 GRP mRNA is also highly expressed in small cell lung carcinoma despite the lack of immunoreactivity for the final product. 26 Hamid et al were unable to identify chromogranin mRNA in any non-small cell lung carcinoma, but the same authors found GRP mRNA in seven of 10 non-small cell lung tumours. 18 26 Routinely processed small cell biopsy material does not at present lend itselfreadily to in situ hybridisation, but there are rapid technical advances and it seems certain that molecular biology will make a significant impact in this field.27 It will also cause us to question our definition of neuroendocrine differentiation. Genetic material encoding for specific peptides may be present in most lung carcinoma cells, but is the presence of mRNA sufficient or should we require evidence of protein translation?
Another approach has been to produce monoclonal antibodies against different types of lung carcinoma. Analysis of the data from a series of three international workshops has identified 15 10 which consists of three neuroendocrine-specific proteins localised in the endoplasmic reticulum.3' Unfortunately, the use of these antibodies is limited by their availability and because they are not generally applicable to formalin fixed, paraffin embedded tissue. With current methods of antigen retrieval, using microwaves or pressure cookers, further assessment of this group is possible. To clinicians, who are generally content with the distinction between small cell lung carcinoma and non-small cell lung carcinoma, it must seem that pathologists are placing undue emphasis on the recognition of neuroendocrine differentiation. For them the obvious questions must be: does it have clinical significance and does it have prognostic or therapeutic implications? Clearly a diagnosis of small cell lung carcinoma has all these things, but it is by no means certain that its aggressive clinical behaviour or its sensitivity to chemotherapy and radiotherapy are in any way directly related to its neuroendocrine features per se. In non-small cell lung carcinoma only very careful clinicopathological studies, with consistent classification and reliable markers, can determine whether neuroendocrine differentiation, as an independent variable, indicates a better or worse prognosis or should influence assessment and treatment. The evidence so far is unclear; if neuroendocrine differentiation is defined using conventional, commercially available antibodies, there is some evidence that it is associated with greater metastatic potential, in terms of nodal status and stage, and with increased response to chemotherapy, but it is doubtful whether this influences survival. 14 32 33 The antibody 1 23C3 to NCAM identifies a group of non-small cell lung cancers (about 20%) with a shorter postoperative and disease-free survival than NCAM-negative tumours. 30 There is no "gold standard" for neuroendocrine differentiation. We do not have sufficient confidence in any of the antibodies available to say that it stains with antibody X therefore neuroendocrine differentiation must be present, regardless ofits cell type. We have to begin by classifying the tumours by traditional morphological means and assessing immunoreactivity against this. The problem is compounded by differences in sensitivity and specificity for identical antibodies in different hands, reflecting many different variables in fixation, processing, staining techniques, and interpretation. When an antibody that appears to be consistently reactive with tumours diagnosed as small cell lung carcinoma also stains, for example, squamous cell carcinomas, this is, quite reasonably, interpreted as evidence of neuroendocrine differentiation in some tumours of overtly squamous cell phenotype.
On this basis several studies, including the current one, indicate that, of the commercially available antibodies, the most specific markers are synaptophysin and chromogranin A. Leu-7 would be a reasonable third choice, although it seems to stain more non-small cell lung carcinomas than the other two.'0 1519 The use of a panel of antibodies has been recommended, with the suggestion that reactivity with two or more should be required before neuroendocrine differentiation is accepted.'53233 The evidence is that greater confidence should be placed in these three antibodies than other markers, but they may shortly be complemented or displaced by antibodies to NCAM and other more specific tumour antigens. This is the best we can offer at present but, by concentrating on neuroendocrine differentiation, we are probably seeing only one facet of a more fundamental change that endows some lung carcinomas with more aggressive properties. It is likely that other characteristics, such as proto-oncogene expression, may eventually provide us with more insight into the nature of this change.
